Polycyclic carbamoylpyridone derivatives, pharmaceutical compositions and use thereof

1. A polycyclic carbamoylpyridone derivative as shown in formula (VII), a stereoisomer thereof, a tautomer thereof, a hydrate thereof, a solvate thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof,

wherein,

R 1 is hydrogen or deuterium;

R 2 is hydrogen or deuterium;

R 3 is hydrogen or deuterium;

L is hydrogen, alkyl, or (methoxycarbonyl) oxymethyl;

and at least one of R 1 , R 2 and R 3 is deuterium;

R 4 is hydrogen or halogen;

R 5 is hydrogen or halogen;

R 6 is hydrogen or halogen;

A is C or O, when A is C, then both R 7 and R 8 are hydrogen or both R 7 and R 8 are methyl;

when A is O, then R 7 and R 8 do not exist;

R 9 is hydrogen or methyl; R 10 is hydrogen or methyl;

and R 4 , R 5 and R 6 are not hydrogen simultaneously.

2. The polycyclic carbamoylpyridone derivative as shown in formula (VII), the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 1 ,

wherein the polycyclic carbamoylpyridone derivative as shown in formula (VII) satisfies any one of the following conditions:

condition 1: R 4 is hydrogen; R 5 is fluorine; R 6 is fluorine; A is O; R 9 is hydrogen; R 10 is hydrogen;

condition 2: R 4 is hydrogen; R 5 is fluorine; R 6 is hydrogen; A is O; R 9 is hydrogen; R 10 is methyl and the configuration of carbon atom directly connected with R 10 is(S);

condition 3: R 4 is chlorine; R 5 is hydrogen; R 6 is hydrogen; A is O; R 9 is hydrogen; R 10 is hydrogen;

condition 4: R 4 is hydrogen; R 5 is fluorine; R 6 is fluorine; A is C; both R 7 and R 8 are methyl; R 9 is hydrogen; R 10 is hydrogen;

condition 5: R 4 is hydrogen; R 5 is fluorine; R 6 is fluorine; A is C; both R 7 and R 8 are hydrogen; R 9 is hydrogen and the configuration of carbon atom directly connected with R 9 is (R); R 10 is hydrogen;

condition 6: R 4 is hydrogen; R 5 is fluorine; R 6 is hydrogen; A is C; both R 7 and R 8 are hydrogen; R 9 is hydrogen; R 10 is hydrogen.

3. A polycyclic carbamoylpyridone derivative as shown in formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI), a stereoisomer thereof, a tautomer thereof, a hydrate thereof, a solvate thereof, a crystal form thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof,

in the formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI),

R 1 is independently hydrogen or deuterium;

R 2 is independently hydrogen or deuterium;

R 3 is independently hydrogen or deuterium;

L is independently hydrogen, alkyl or (methoxycarbonyl) oxymethyl;

and, in each of the formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI), at least one of R 1 , R 2 and R 3 is deuterium.

4. The polycyclic carbamoylpyridone derivative as shown in formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI), the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 3 , wherein,

the polycyclic carbamoylpyridone derivative as shown in formula (I) is selected from the group consisting of:

or, the polycyclic carbamoylpyridone derivative as shown in formula (II) is selected from the group consisting of:

or, the polycyclic carbamoylpyridone derivative as shown in formula (III) is selected from the group consisting of:

or, the polycyclic carbamoylpyridone derivative as shown in formula (IV) is selected from the group consisting of:

or, the polycyclic carbamoylpyridone derivative as shown in formula (V) is selected from the group consisting of:

or, the polycyclic carbamoylpyridone derivative as shown in formula (VI) is selected from the group consisting of:

5. The polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as claimed in claim 1 , wherein,

the pharmaceutically acceptable salt thereof is an acid addition salt formed by the polycyclic carbamoylpyridone derivative as shown in formula (VII) and an organic acid or an inorganic acid; wherein, the organic acid is one or more selected from the group consisting of maleic acid, fumaric acid, benzoic acid, ascorbic acid, succinic acid, methanesulfonic acid, acetic acid, trifluoroacetic acid, oxalic acid, propionic acid, tartaric acid, salicylic acid, citric acid, gluconic acid, lactic acid, mandelic acid, phenylacetic acid, aspartic acid, stearic acid, palmitic acid, glycolic acid, glutamic acid and benzenesulfonic acid; the inorganic acid is one or more selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and nitric acid;

or, the pharmaceutically acceptable salt thereof is a salt formed by the polycyclic carbamoylpyridone derivative as shown in formula (VII) and one or more organic and inorganic cations selected from the group consisting of alkali metal ions, alkaline earth metal ions and ammonium ions; wherein, the alkali metal is selected from lithium, sodium, or potassium; and the alkaline earth metal is selected from magnesium, barium, or calcium.

6. A pharmaceutical composition comprising a therapeutically effective amount of the polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 1 , and a pharmaceutically acceptable carrier.

7. The pharmaceutical composition as defined in claim 6 , further comprising other active pharmaceutical ingredient, and the other active pharmaceutical ingredient is selected from neuraminidase inhibitors, RNA-dependent RNA polymerase inhibitors, M2 protein inhibitors, PB2 Cap binding inhibitors, anti-HA antibodies, or immune action drugs.

8. The pharmaceutical composition as defined in claim 7 , wherein the neuraminidase inhibitor is oseltamivir, zanamivir, peramivir, or Inavir; the RNA-dependent RNA polymerase inhibitor is favipiravir; the M2 protein inhibitor is amantadine; the PB2 Cap binding inhibitor is VX-787; the anti-HA antibody is MHAA4594A; the immune action drug is nitazoxanide.

9. A method for treating and/or alleviating a disease in an individual in need thereof, comprising: administering an effective amount of the polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 1 to the individual to inhibit the in vivo level of 5′cap-dependent endonuclease of the individual, wherein the disease refers to a symptom and/or disease caused by influenza virus infection.

10. The method as defined in claim 9 , wherein the influenza virus is selected from type A, type B, or type C.

11. The method as defined in claim 9 , wherein the symptom is selected from cold-like symptoms of fever, chill, headache, muscle pain, general fatigue, and the like, or respiratory tract inflammations of sore throat, runny nose, nasal congestion, cough, sputum; gastrointestinal symptoms of abdominal pain, vomiting, diarrhea; and further complications of secondary infection of acute encephalopathy, pneumonia.

12. The polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 3 , wherein,

the pharmaceutically acceptable salt thereof is an acid addition salt formed by the polycyclic carbamoylpyridone derivative as shown in formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI) and an organic acid or an inorganic acid; wherein, the organic acid is one or more selected from the group consisting of maleic acid, fumaric acid, benzoic acid, ascorbic acid, succinic acid, methanesulfonic acid, acetic acid, trifluoroacetic acid, oxalic acid, propionic acid, tartaric acid, salicylic acid, citric acid, gluconic acid, lactic acid, mandelic acid, phenylacetic acid, aspartic acid, stearic acid, palmitic acid, glycolic acid, glutamic acid and benzenesulfonic acid; the inorganic acid is one or more selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and nitric acid;

or, the pharmaceutically acceptable salt thereof is a salt formed by the polycyclic carbamoylpyridone derivative as shown in formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI) and one or more organic and inorganic cations selected from the group consisting of alkali metal ions, alkaline earth metal ions and ammonium ions; wherein, the alkali metal is selected from lithium, sodium, or potassium; and the alkaline earth metal is selected from magnesium, barium, or calcium.

13. The polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 4 , wherein,

the pharmaceutically acceptable salt thereof is an acid addition salt formed by the polycyclic carbamoylpyridone derivative as shown in formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI) and an organic acid or an inorganic acid; wherein, the organic acid is one or more selected from the group consisting of maleic acid, fumaric acid, benzoic acid, ascorbic acid, succinic acid, methanesulfonic acid, acetic acid, trifluoroacetic acid, oxalic acid, propionic acid, tartaric acid, salicylic acid, citric acid, gluconic acid, lactic acid, mandelic acid, phenylacetic acid, aspartic acid, stearic acid, palmitic acid, glycolic acid, glutamic acid and benzenesulfonic acid; the inorganic acid is one or more selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and nitric acid;

or, the pharmaceutically acceptable salt thereof is a salt formed by the polycyclic carbamoylpyridone derivative as shown in formula (I), formula (II), formula (III), formula (IV), formula (V), or formula (VI) and one or more organic and inorganic cations selected from the group consisting of alkali metal ions, alkaline earth metal ions and ammonium ions; wherein, the alkali metal is selected from lithium, sodium, or potassium; and the alkaline earth metal is selected from magnesium, barium, or calcium.

14. A pharmaceutical composition comprising a therapeutically effective amount of the polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 3 , and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition as defined in claim 14 , further comprising other active pharmaceutical ingredient, and the other active pharmaceutical ingredient is selected from neuraminidase inhibitors, RNA-dependent RNA polymerase inhibitors, M2 protein inhibitors, PB2 Cap binding inhibitors, anti-HA antibodies, or immune action drugs.

16. A pharmaceutical composition comprising a therapeutically effective amount of the polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 4 , and a pharmaceutically acceptable carrier.

17. The pharmaceutical composition as defined in claim 16 , further comprising other active pharmaceutical ingredient, and the other active pharmaceutical ingredient is selected from neuraminidase inhibitors, RNA-dependent RNA polymerase inhibitors, M2 protein inhibitors, PB2 Cap binding inhibitors, anti-HA antibodies, or immune action drugs.

18. A method for treating, and/or alleviating a disease in an individual in need thereof, comprising: administering an effective amount of the polycyclic carbamoylpyridone derivative, the tautomer thereof, the hydrate thereof, the solvate thereof, the active metabolite thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 3 to the individual to inhibit the in vivo level of 5′cap-dependent endonuclease of the individual, wherein the disease refers to a symptom and/or disease caused by influenza virus infection.

19. A method for treating and/or alleviating a disease in an individual in need thereof, comprising: administering an effective amount of the polycyclic carbamoylpyridone derivative, the stereoisomer thereof, the tautomer thereof, the hydrate thereof, the solvate thereof, the crystal form thereof, the pharmaceutically acceptable salt thereof, or the prodrug thereof as defined in claim 4 to the individual to inhibit the in vivo level of 5′cap-dependent endonuclease of the individual, wherein the disease refers to a symptom and/or disease caused by influenza virus infection.